What are the indications for switching a patient from sublingual Suboxone (buprenorphine‑naloxone) to monthly injectable Sublocade (extended‑release buprenorphine)?

Indications for Switching from Suboxone to Sublocade

Patients should be transitioned from sublingual Suboxone to monthly injectable Sublocade when they are stabilized on 8-24 mg daily of transmucosal buprenorphine and would benefit from improved adherence, reduced diversion risk, or elimination of daily dosing burden. 1

Primary Clinical Indications

1. Adherence and Stability Optimization

• Patients stabilized on daily sublingual therapy who demonstrate good treatment response but struggle with daily medication adherence 1
• Those who are bothered by the daily intake requirement and would prefer monthly dosing 2
• Patients who have graduated to less frequent clinic visits (weekly or less) and demonstrate treatment stability 3

2. High-Risk Populations Requiring Enhanced Support

Recently incarcerated individuals:

• Patients recently released from jail or prison face extremely high overdose risk and benefit from guaranteed monthly dosing that cannot be interrupted 4
• This population has historically poor retention with daily medications

Unstably housed patients:

• Those experiencing homelessness who may have difficulty maintaining daily medication schedules 4
• Monthly injections ensure continuous treatment despite housing instability

Patients with ongoing illicit opioid use:

• Those who remain unstable and continue using opioids illicitly despite sublingual therapy may benefit from the steady-state plasma levels achieved with monthly injections 4

3. Diversion and Misuse Prevention

• Patients with concerns about medication diversion (selling or sharing medication) 2
• Those with household members at risk for accidental exposure or misuse 1
• Situations where supervised administration is preferred but daily clinic visits are impractical

4. Treatment Completion Strategy

• Patients ready to discontinue buprenorphine who have been unable to taper off sublingual formulations due to withdrawal symptoms 5
• A single 100 mg injection can facilitate transition to opioid cessation by providing gradual tapering over months 5

Dosing Transition Algorithm

For patients on 8-24 mg daily sublingual buprenorphine:

• Start with 300 mg Sublocade as initial injection
• Second injection: 300 mg (given 1 week to 1 month after first dose based on patient need) 1
• Maintenance: 100 mg monthly for most patients 1

For patients on 8-18 mg daily who remain well-controlled:

• May transition to 100 mg monthly as early as the second injection if symptoms remain controlled after initial 300 mg dose 1

For patients requiring higher maintenance:

• 300 mg monthly may be considered for those who tolerate 100 mg but lack satisfactory clinical response 1

Critical Considerations

Pharmacokinetic Differences

At steady state, Sublocade provides:

• Lower peak concentrations than sublingual formulations
• Higher average and trough concentrations throughout the dosing interval 1
• This creates more stable plasma levels, potentially reducing cravings and withdrawal between doses

Long-Term Detection

• Buprenorphine remains detectable in plasma for 22-38 months after the last injection 1
• Urine detection persists even longer and is more variable 1
• Patients must understand this extended detection window before transitioning

Contraindications to Switching

Do not transition patients who:

• Are on less than 8 mg daily sublingual buprenorphine (insufficient stabilization) 1
• Have active injection site infections or conditions preventing subcutaneous injection
• Are pregnant (limited safety data; sublingual buprenorphine-naloxone can be continued) 6
• Have not demonstrated stability on transmucosal formulations

Common Pitfalls to Avoid

1. Premature transition: Patients must be stabilized on sublingual therapy first; direct induction onto Sublocade requires careful monitoring and may need supplemental transmucosal buprenorphine on injection day 1

2. Inadequate patient counseling: Patients must understand the irreversible nature of the depot injection—once administered, buprenorphine will be released over months and cannot be removed 1

3. Ignoring drug interactions: Continue monitoring for CYP3A4 inhibitors/inducers and QT-prolonging agents, as interactions persist with injectable formulations 7, 1

4. Failure to address pain management: For patients using buprenorphine for both OUD and chronic pain, ensure the monthly dosing provides adequate analgesia; some may require divided dosing strategies that are not possible with monthly injections 3